The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Findings from the phase I clinical trials of CX-4945, an orally available inhibitor of CK2.
R. F. Marschke
Research Funding - Cylene
M. J. Borad
Research Funding - Cylene
R. W. McFarland
Research Funding - Cylene
R. H. Alvarez
Research Funding - Cylene
J. K. Lim
Employment or Leadership Position - Cylene
C. S. Padgett
Employment or Leadership Position - Cylene
D. D. Von Hoff
Employment or Leadership Position - Cylene
Consultant or Advisory Role - Cylene
Stock Ownership - Cylene
S. E. O'Brien
Employment or Leadership Position - Cylene
D. W. Northfelt
Research Funding - Cylene